Parihar Vikas, Katz Laura, Siyam Mahmoud A, Rogers Anna, Patterson Lisa, Zacharias Ramesh
BSc(Pharm), PharmD. Michael G. DeGroote Pain Clinic, Hamilton Health Sciences, & Department of Anesthesia, McMaster University. Hamilton, ON (Canada).
PhD, CPsych. Michael G. DeGroote Pain Clinic, Hamilton Health Sciences, & Department of Psychology, Neuroscience and Behavior, McMaster University. Hamilton, ON (Canada).
Pharm Pract (Granada). 2020 Oct-Dec;18(4):2088. doi: 10.18549/PharmPract.2020.4.2088. Epub 2020 Nov 30.
The primary objectives of this pre-post session study, was to evaluate the impact of a pharmacist-led education session on the perceived benefits and safety of cannabis among patients with chronic pain, as well as determine the influence of pharmacist education on the selection of safer cannabis products and dosage forms for medical use among patients.
A retrospective analysis of completed pre-post session questionnaires was conducted among chronic pain patients attending a mandatory education session led by a pharmacist, prior to being authorized cannabis in clinic. All questionnaire data was analyzed using SPSS v. 25. Demographic and sample characteristics were reviewed using univariate analyses. Chi-Square tests were employed to determine if the group-based education significantly affected knowledge, perception of efficacy and safety of cannabis.
Of the 260 session participants, 203 completed pre-post session questionnaires. After the session, a majority of current cannabis users (33.8%) and cannabis naïve/past users (56.9%) reported they would use a low THC product in the future, and a majority of current users (54.5%) would use a high CBD product in the future. After education, participants were more likely to report cannabis as having the potential for addiction (chi-square =42.6, p <0.0001) and harm (chi-square =34.0, p <0.0001).
Pharmacist counselling and education has the potential to influence patient selection and use of cannabis, from more harmful to safer products, as well as moderate the potential perceived benefits of use.
本前后对照研究的主要目的是评估药剂师主导的教育课程对慢性疼痛患者对大麻感知益处和安全性的影响，并确定药剂师教育对患者选择更安全的医用大麻产品和剂型的影响。
对参加药剂师主导的强制教育课程的慢性疼痛患者进行回顾性分析，这些患者在诊所获得大麻授权之前完成了课程前后的问卷调查。所有问卷数据均使用SPSS v. 25进行分析。使用单变量分析回顾人口统计学和样本特征。采用卡方检验确定基于小组的教育是否显著影响对大麻的知识、疗效和安全性的认知。
在260名课程参与者中，203人完成了课程前后的问卷调查。课程结束后，大多数当前大麻使用者（33.8%）和从未使用过/过去使用过大麻的人（56.9%）表示他们未来会使用低四氢大麻酚（THC）产品，大多数当前使用者（54.5%）未来会使用高大麻二酚（CBD）产品。教育后，参与者更有可能报告大麻有成瘾（卡方=42.6，p<0.0001）和有害（卡方=34.0，p<0.0001）的可能性。
药剂师的咨询和教育有可能影响患者对大麻的选择和使用，使其从更有害的产品转向更安全的产品，并调节使用大麻可能感知到的益处。
